#Urothelial Cancer Treatment Market share

[businessindustry]

Urothelial Cancer Treatment Market Forecast, Analysis | Reports and Insights | 2024-2032

The Reports and Insights, a leading market research company, has recently releases report titled “Urothelial Cancer Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2031.” The study provides a detailed analysis of the industry, including the global Urothelial Cancer Treatment Market Share size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Urothelial Cancer Treatment Market?

The global urothelial cancer treatment market was US$ 1.1 Billion in 2022. Furthermore, the global market to register revenue CAGR of 9.5% over the forecast period and account for market size of US$ 2.5 Bn in 2031.

What are Urothelial Cancer Treatment?

Urothelial cancer treatment varies depending on the cancer's stage and severity. It usually involves surgery to remove the tumor or affected organ, such as the bladder, followed by chemotherapy or immunotherapy to kill any remaining cancer cells and prevent recurrence. In cases where the cancer has spread, additional treatments like radiation therapy or targeted therapy may be used. Treatment plans are personalized based on the individual's health and preferences, with the goal of achieving the best outcomes while minimizing side effects.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2055

What are the growth prospects and trends in the Urothelial Cancer Treatment industry?

The urothelial cancer treatment market growth is driven by various factors. The market for urothelial cancer treatment is experiencing notable growth, primarily due to the escalating global incidence of this cancer type. Key drivers include a growing elderly population, lifestyle shifts increasing cancer risks, and advancements in treatment methodologies. The introduction of innovative therapies like immunotherapy and targeted therapy is also propelling market expansion. Nevertheless, obstacles such as the high cost of treatment and restricted access to advanced cancer care in developing areas could impede market growth. Hence, all these factors contribute to urothelial cancer treatment market growth.

What is included in market segmentation?

The report has segmented the market into the following categories:

By Treatment Type:

Chemotherapy

Immunotherapy

Targeted Therapy

Surgery

Radiation Therapy

By End-Use:

Hospitals

Cancer Treatment Centers

Ambulatory Surgical Centers

Specialty Clinics

Others

By Drug Type:

Platinum-based Chemotherapy Drugs

Immune Checkpoint Inhibitors

FGFR Inhibitors

PD-L1 Inhibitors

Others

By Cancer Stage:

Non-Muscle Invasive Bladder Cancer (NMIBC)

Muscle Invasive Bladder Cancer (MIBC)

Metastatic Urothelial Carcinoma

Others

Segmentation By Region:

North America:

United States

Canada

Asia Pacific:

China

India

Japan

Australia & New Zealand

Association of Southeast Asian Nations (ASEAN)

Rest of Asia Pacific

Europe:

Germany

The U.K.

France

Spain

Italy

Russia

Poland

BENELUX (Belgium, the Netherlands, Luxembourg)

NORDIC (Norway, Sweden, Finland, Denmark)

Rest of Europe

Latin America:

Brazil

Mexico

Argentina

Rest of Latin America

The Middle East & Africa:

Saudi Arabia

United Arab Emirates

South Africa

Egypt

Israel

Rest of MEA (Middle East & Africa)

Who are the key players operating in the industry?

The report covers the major market players including:

Merck & Co., Inc.

Genentech, Inc. (Roche)

Bristol Myers Squibb

Eli Lilly and Company

AstraZeneca

Seattle Genetics

Johnson & Johnson (Janssen Pharmaceuticals)

Pfizer Inc.

Novartis International AG

Sanofi S.A.

View Full Report: https://www.reportsandinsights.com/report/Urothelial Cancer Treatment-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: sales@reportsandinsights.com Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1

[stevenwilliam12]

Target Population Dynamics and FGFR Market Growth Forecast: Key Insights to 2034

Introduction to the FGFR Market

The fibroblast growth factor receptor (FGFR) family plays a pivotal role in cell growth, differentiation, angiogenesis, and survival. FGFR signaling is implicated in various cancers and other diseases, making it a significant target for drug development. As a result, the FGFR market is witnessing considerable growth, with a focus on therapies targeting FGFR mutations and pathways. This article provides a comprehensive overview of the FGFR market size, target population, competitive landscape, and a market forecast through 2034.

Market Size and Growth Drivers

The FGFR inhibitors market has grown steadily over the last decade due to advancements in targeted therapies and the increasing incidence of cancers with FGFR mutations, such as bladder, breast, liver, and lung cancers. The FGFR market's growth is driven by:

Rising Cancer Incidence: A significant driver for FGFR-targeted therapies is the increasing incidence of FGFR-mutant cancers globally. Bladder, cholangiocarcinoma, and lung cancers show high FGFR mutation prevalence, making them a prime focus for FGFR inhibitors.

Innovative Targeted Therapies: FGFR inhibitors have shown promise in selectively targeting cancer cells with FGFR mutations, leading to enhanced efficacy and minimized adverse effects.

Regulatory Support and Orphan Drug Designations: Regulatory bodies, including the FDA and EMA, have accelerated the development of FGFR-targeted therapies, with several FGFR inhibitors receiving orphan drug designations, expedited review, and priority designations.

Target Population and Key Therapeutic Areas

The FGFR market encompasses multiple patient segments across various cancer types. Some key areas include:

Bladder Cancer: FGFR3 mutations are commonly found in urothelial bladder cancer, making it a significant segment for FGFR inhibitors. Erdafitinib, approved for FGFR-mutant bladder cancer, is a leading therapy in this space.

Cholangiocarcinoma: FGFR2 fusion mutations are prevalent in cholangiocarcinoma, creating a strong demand for targeted treatments in this patient population.

Lung and Breast Cancer: FGFR mutations are observed in subsets of patients with lung and breast cancers, presenting additional opportunities for FGFR-targeted therapies.

Pediatric Conditions: In addition to oncology, FGFR inhibitors are being explored for pediatric skeletal dysplasias, such as achondroplasia, offering potential non-cancer applications for these drugs.

Competitive Landscape: Key Players and Products

The FGFR inhibitors market features a mix of established pharmaceutical companies and innovative biotech firms actively developing FGFR-targeted therapies. Key players in the competitive landscape include:

Janssen Pharmaceuticals: Janssen’s Erdafitinib (Balversa) is one of the first FGFR inhibitors approved for FGFR-mutant bladder cancer, positioning the company as a leader in FGFR-targeted oncology treatments.

Incyte Corporation: Incyte’s Pemigatinib (Pemazyre) targets FGFR2 fusions in cholangiocarcinoma and has received regulatory approval in multiple regions, making it a front-runner for FGFR-targeted therapy in biliary cancers.

Blueprint Medicines: With Pralsetinib and Avapritinib targeting FGFR pathways, Blueprint Medicines is expanding its footprint in precision oncology, leveraging its expertise in kinase inhibitors to address FGFR-driven tumors.

QED Therapeutics: The biotech firm QED Therapeutics has developed Infigratinib, an FGFR1–3 inhibitor focused on cholangiocarcinoma and bladder cancer. Infigratinib is positioned to capture market share in these segments as an FGFR-targeted therapy.

Roche/Genentech: Roche is investing heavily in research to develop FGFR inhibitors, targeting both FGFR-mutant cancers and rare conditions involving FGFR dysregulation.

These companies are exploring both monotherapy and combination therapies with FGFR inhibitors to improve response rates and address resistance mechanisms in various cancers.

FGFR Inhibitors in Clinical Trials

Several FGFR-targeted therapies are in various phases of clinical development, addressing a wide range of cancers and genetic disorders. Ongoing clinical trials are focused on optimizing the dosage, efficacy, and safety profiles of FGFR inhibitors, with promising results emerging from Phase II and III studies.

For instance:

Erdafitinib is being evaluated in combination with immune checkpoint inhibitors for bladder cancer.

Pemigatinib is undergoing trials for broader applications in solid tumors with FGFR alterations.

Novel FGFR inhibitors are being developed to overcome resistance in patients with mutations in the FGFR1–3 genes, which limit the efficacy of current therapies.

These trials play a crucial role in determining optimal patient populations, dosing schedules, and combination strategies, ultimately guiding the future of FGFR-targeted treatments.

FGFR Market Forecast to 2034

Looking ahead, the FGFR market is anticipated to grow significantly through 2034, with a robust CAGR driven by:

Expanded Indications: The identification of FGFR mutations across multiple cancer types will expand the potential market for FGFR inhibitors, leading to a broader target population.

Combination Therapies: Combining FGFR inhibitors with immune-oncology drugs and other targeted therapies is likely to enhance efficacy, reduce drug resistance, and improve long-term outcomes, fueling further market growth.

Personalized Medicine and Diagnostics: Advances in molecular diagnostics will facilitate earlier detection of FGFR mutations, ensuring that patients receive targeted therapies tailored to their genetic profiles. This personalized approach is expected to drive adoption of FGFR inhibitors and improve outcomes.

Strategic Collaborations and Partnerships: Collaborations between pharmaceutical companies, research institutions, and biotech firms are expected to expedite the development and commercialization of FGFR therapies, expanding the market and accelerating patient access to new treatments.

Orphan Designations and Regulatory Support: With several FGFR inhibitors receiving orphan drug and fast-track designations, companies are likely to benefit from reduced time-to-market, encouraging continued investment in FGFR-targeted drug development.

Conclusion

The FGFR market is poised for dynamic growth, driven by the increasing incidence of FGFR-mutant cancers, innovative therapies, and supportive regulatory environments. As research uncovers new applications for FGFR inhibitors in oncology and rare diseases, the market landscape will continue to expand, offering promising treatment options for a range of challenging conditions. With an expanding pipeline, strategic collaborations, and advancements in molecular diagnostics, FGFR-targeted therapies are set to transform patient care, providing hope for improved outcomes across oncology and beyond.

Latest Reports

Contraceptive Devices Market | Crohns Disease Cd Market | Cutaneous T-cell Lymphoma Market | Diabetic Neuropathy Market | Ehlers-danlos Syndrome Market | Encephalitis Market | Epidermolysis Bullosa Market | Familial Amyloid Polyneuropathy Market | Healthcare Competitive Benchmarking | Hepatic Encephalopathy Epidemiology Forecast | Hepatitis B Virus Market | Hepatitis D Market | Hereditary Spastic Paraplegias Market | Hpv-induced Cancers Market | Human Papillomavirus Positive Cancer Market | Hyperkalemia Market | Nontuberculous Mycobacteria Infection Market | Post-bariatric Hypoglycemia Market | Postsurgical Pain Market | Primary Progressive Multiple Sclerosis Ppms Market | Surgical Stapling Devices Market | Vascular Access Devices Market | Vascular Dementia Market | Wound Closure Devices Market | Xerostomia Market

[omkarpatel]

Atezolizumab Market is Estimated to Witness High Growth Owing to Opportunity of Increasing Cancer Treatment

Atezolizumab is a type of immunotherapy drug known as a programmed death-ligand 1 (PD-L1) inhibitor. It works by blocking PD-L1 and restoring the anti-tumor immune response in patients. Atezolizumab is used to treat various forms of cancer including non-small cell lung cancer (NSCLC), urothelial carcinoma and other solid tumors. The need for effective cancer treatment options is increasing globally owing to rising cancer prevalence. The global Atezolizumab Market is estimated to be valued at US$ 308 Million in 2023 and is expected to exhibit a CAGR of 3.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The increasing prevalence of cancer presents a major market opportunity for atezolizumab. According to WHO, cancer burden has risen to 18.1 million new cases and 9.6 million cancer deaths in 2018 globally. Lung cancer is the most common cancer worldwide. Atezolizumab is indicated for treatment of NSCLC and has potential to capture significant market share due to its efficacy and survival benefits over chemotherapy. Furthermore, ongoing clinical trials evaluating atezolizumab for new cancer indications such as breast cancer, gastric cancer provide opportunities for label expansion. This will increase the eligible patient pool and volumes, driving the atezolizumab market growth over the forecast period. Porter's Analysis Threat of new entrants: The biopharmaceutical industry requires high R&D investment and manufacturing costs which creates significant barriers for new entrants. Bargaining power of buyers: The bargaining power of buyers is moderate as major pharmaceutical companies have patent protection for their drugs. Bargaining power of suppliers: Suppliers have moderate bargaining power due to the availability of alternative suppliers in the pharmaceutical supply chain. Threat of new substitutes: The threat of new substitutes is high as newer targeted therapies are constantly emerging in the oncology segment. Competitive rivalry: The competitive rivalry is high among existing players due to frequent product launches and patent expirations. SWOT Analysis Strength: Atezolizumab has a well-established safety and efficacy profile for treating various cancers like non-small cell lung cancer and urothelial carcinoma based on positive clinical trial results. Weakness: High costs associated with immunotherapies like Atezolizumab burden the healthcare systems. Drug development also requires lengthy approval timelines. Opportunity: Increasing adoption rates of immunotherapies globally presents an opportunity to expand into new cancer indications and treatment combinations. Threats: Generic competition post patent expiration of Atezolizumab poses pricing pressures. Side effects of immunotherapies continue to be a concern. Key Takeaways The global Atezolizumab market is expected to witness high growth. Regional Analysis: North America is expected to dominate the market during the forecast period owing to rising cancer incidence and higher adoption of novel therapeutics. The Asia Pacific region is projected to grow at the fastest rate fueled by growing cancer burden, awareness, and improving access to targeted therapies. Key players operating in the Atezolizumab market are Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc. Their focus is on expanding indications through ongoing clinical trials to sustain market position.

[rootsanalysis-blog]

TOP SELLING BIOLOGICS MARKET - CURRENT MARKET LANDSCAPE

The “Top Selling Biologics Market, report features an extensive study of the current market landscape and future potential of the top selling biologics available for the treatment of a variety of disease indications.

 As of today, most of the top revenue generating drugs, across the globe, are biologics. During our biologics market research, we were able to identify 67 top selling biologics (revenues equal to or above USD 500 million in 2020). Top selling biologics market has so far been primarily led by industry players. Majority of industry players have taken a step towards investing their time and resources for the development of biologic therapies. Genentech, Amgen, Janssen Biotech, Sanofi and Novo Nordisk are amongst the major players in this domain. Biogen, AstraZeneca, Merck, Bristol Myers Squibb, GlaxoSmithKline, Alexion Pharmaceuticals, AbbVie and Novartis are other players that have entered the Top Selling Biologics domain in the past.

 To request a sample report: https://www.rootsanalysis.com/reports/top-selling-biologics-market/request-sample.html

 It is worth highlighting that most of the therapies are monoclonal antibodies capture the highest share (54%) of the top selling biologics market. This can be attributed to the various advantages offered by them, including high reproducibility and specificity. It is also worth mentioning that these therapeutic modalities are being used for many cancer indications. Further, most of the top selling biologics are currently delivered via subcutaneous route of administration. However, most of the top selling biologics are available in the form of vials. This can be attributed to the better sterility assurance and reduced particle presence offered by such packaging formats.

 To order customize report: https://www.rootsanalysis.com/reports/top-selling-biologics-market/request-customization.html

 It is worth highlighting that most of the therapies are being developed against autoimmune and oncological disorders; Oncological indications targeted by biologics include colorectal cancer (6), Non-Small Cell Lung Cancer (3), Breast Cancer (3), Hepatocellular Carcinoma (3), bladder cancer (3), urothelial carcinoma (3), and melanoma (3).

 For more information, please click on the following link:

https://www.rootsanalysis.com/reports/top-selling-biologics-market.html

 You may also be interested in the following reports:

1.      Antibody Drug Conjugates Market

2.      Cell and Gene Therapy CROs Market

3.      Bispecific Antibody Therapeutics Market

4.      Genome Editing Services Market

  About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

[wemarketresearchreport]

Antibody Drug Conjugates Market Key Vendors, Key Segment, Key Companies, Growth Opportunities by 2022-2030

The Antibody Drug Conjugates Market  is appreciated to demonstrate a substantial upswing of a CAGR of 12.9% during the forecasted period of 2023 to 2030. The Antibody Drug Conjugates Market is set to be valued at USD 3,198 billion in 2023 and is estimated to display a significant improvement of USD 7475.74 billion by 2030.

Monoclonal antibodies, linkers, drugs or toxins, and others are the most common types of antibody drug conjugates. A single white blood cell is cloned to produce monoclonal antibodies. Every successive antibody can be traced back to a single parent cell in this way. Adcertis, Kadcyla, and other products are involved, as are numerous technologies such as immunogen technology, Seattle Genetics technology, Immunomedics technology, and others. It is used to treat blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumours, and other cancers, and it is utilised in hospitals, clinics, and other settings.

Request a sample copy of Antibody Drug Conjugates Market: https://wemarketresearch.com/sample-request/antibody-drug-conjugates-market/132/

Global Antibody Drug Conjugates Market- Segmental Analysis

Market has been segmented into sections namely, Drugs, Mechanism of Action, Application, Technology, End User

Key Players:-

·        AbbVie Inc.

·        ADC Therapeutics

·        Agensys Inc.

·        Antikor

·        Astellas Pharma, ADC Therapeutics

·        Bayer AG

·        Celldex Therapeutics

·        Concortis Biotherapeutics

·        Daiichi Sankyo Company Ltd.

·        Genentech

·        Gilead Sciences, Inc.

·        GlaxoSmithKline Plc

·        Heidelberg Pharma

·        ImmunoGen Inc.

·        Immunomedics Inc.

·        Mersana Therapeutics

·        Millennium Pharmaceuticals

·        Oxford Biotherapeutics.

·        Pfizer Inc.

·        Progenics Pharmaceuticals

·        Roche Holding Ag

·        Seagen, Inc.

·        Seattle Genetics Inc.

·        Synthon

·        Takeda Pharmaceutical Company Limited

Antibody Drug Conjugates Market based on Drugs: Analysis

• Kadcyla

• Adcetris

• Besponsa

• Lumoxiti

• Mylotarg

• Others

Kadcyla was one of the approved drugs by US and Europe for collateral treatment for early patients of HER2-positive breast cancer. The approval of Kadcyla for early-stage treatment is expected to boost the market.

Antibody Drug Conjugates Market by Mechanism of Action: Analysis

• HER2 Antibodies

• CD30 Antibodies

• Others

Antibody Drug Conjugates Market by Application: Analysis

• Lymphoma

• Breast Cancer

• Blood Cancer

• Skin cancer

• Brain Tumor

• Ovary Cancer

• Brain Cancer

• Urothelial & Bladder Cancer

• Other Types of Cancer

Among the application segment the blood cancer segment is anticipated to nurture at a CAGR of 19.4% during the anticipated term. This is attributable to rising incidences of cancerous diseases and approval for ADC’s.

Antibody Drug Conjugates Market by Technology: Analysis

• InnunoGen technology

• Seattle Genetics technology

• Immunomedics technology

• Others

Antibody Drug Conjugates Market by End User: Analysis

On the basis of end use the global antibody drug conjugates market has been segmented into Hospitals, Specialized Cancer Centers, Academic Research Institutes, Biotechnology, Retail Pharmacies, Biopharmaceutical Companies and others. Antibody drug conjugates are used in cancer cell therapy and for research and clinical trials.

Purchase Global Antibody Drug Conjugates Market Research Report:- https://wemarketresearch.com/purchase/antibody-drug-conjugates-market/132/?license=single

Frequently Asked Question About This Report

1.     How are antibody-drug conjugates made?

2.     What are tumour-associated antigens?

3.     What is the usage of antibody-drug conjugates?

4.     What is the expected compound annual growth rate (CAGR) of the market during the forecast period (2021-2028)?

5.     Which segment held the largest antibody-drug conjugate market share?

6.     What was the Antibody-drug Conjugates market size in 2020?

7.     What is the percentage growth rate of antibody-drug conjugates market?

8.     How many antibody-drug conjugates are approved?

About We Market Research

WE MARKET RESEARCH is an established market analytics and research firm with a domain experience sprawling across different industries. We have been working on multi-county market studies right from our inception. Over the time, from our existence, we have gained laurels for our deep rooted market studies and insightful analysis of different markets.

Our strategic market analysis and capability to comprehend deep cultural, conceptual and social aspects of various tangled markets has helped us make a mark for ourselves in the industry. WE MARKET RESEARCH is a frontrunner in helping numerous companies; both regional and international to successfully achieve their business goals based on our in-depth market analysis. Moreover, we are also capable of devising market strategies that ensure guaranteed customer bases for our clients.

Contact Us:

We Market Research

Phone: +1(929)-450-2887

Email: sales@wemarketresearch.com

Web: https://wemarketresearch.com/

[delicatemagazinedreamer]

Urothelial Cancer Treatment Market Share, Growth, Trends & Forecast

Urothelial Carcinoma Treatment Market Status, Trends, and COVID-19 Impact 2021, is an in-depth analysis of market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends, and strategies for this market.

It shows how the market has grown in the past and how it will expand in the future by geography. It compares the market to other markets and places it in the context of the larger Urothelial Carcinoma Treatment Market., market definition, regional market opportunity, sales and revenue by region, manufacturing cost analysis, Industrial Chain

Read more @ https://creativeedge16.blogspot.com/2022/05/urothelial-cancer-treatment-market-size.html

[automotivebatterysensormarket]

Non-Muscle Invasive Bladder Cancer Market Forecast up to 2028.

Non-Muscle Invasive Bladder Cancer Market grows at a CAGR of 22.49% in the forecast period 2021-2028.

Non-Muscle Invasive Bladder Cancer Market: Scope and Market Size

Based on the stage, the non-muscle invasive bladder cancer market is segmented into ta, tis, t1.

Based on the treatment class, the non-muscle invasive bladder cancer market is segmented into chemotherapy, immunotherapy, surgery, radiation therapy, intravesical therapy.

Based on the malignant potential, the non-muscle invasive bladder cancer market is segmented into low-grade tumours, high-grade tumours.

Based on the end-user, the non-muscle invasive bladder cancer market is segmented into hospitals, specialized clinics, others.

For sample report link click here:  https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-non-muscle-invasive-bladder-cancer-market

Non-Muscle Invasive Bladder Cancer Market Share Analysis

Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to non-muscle invasive bladder cancer market.

Browse Full Report : https://www.databridgemarketresearch.com/reports/global-non-muscle-invasive-bladder-cancer-market

Market Analysis & Insights: Non-Muscle Invasive Bladder Cancer Market

The non-muscle invasive bladder cancer market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with the CAGR of 22.49% in the forecast period of 2021 to 2028. The growing number of incidences non-muscle invasive bladder cancer will help in escalating the growth of the non-muscle invasive bladder cancer market.

Non-muscle invasive bladder cancer is usually diagnosed with cystoscopic assessment. Upon analysis, the location, number, and morphology of the tumours are recorded. Urinary cytology and upper tract imaging are done to assess for extravesical urothelial tumours and staging purposes. The common diagnosis method used include cystoscopy, urine cytology, imaging, rigid cystoscopy (Transurethral resection of bladder tumour (TURBT) and blue light cystoscopy).

Non-Muscle Invasive Bladder Cancer Market Level Analysis

The countries covered in the compression therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa(MEA), Brazil, Argentina and Rest of South America as part of South America.

Key Players Non-Muscle Invasive Bladder Cancer Market

HERANTIS PHARMA Plc.

Spectrum Pharmaceuticals, Inc.

Viventia Bio Inc.

Telormedix SA

Bristol-Myers Squibb Company.

F. Hoffmann-La Roche Ltd..

TOC of the report

Chapter One: Introduction

Chapter Two: Market Segmentation

Chapter Three: Market Overview

Chapter Four: Executive Summary

Chapter Five: Premium Insights

Get TOC details from here: https://www.databridgemarketresearch.com/toc/?dbmr=global-non-muscle-invasive-bladder-cancer-market

Get some related Reports @

Europe Compression Therapy Market – Industry Trends and Forecast to 2028

North America Compression Therapy Market – Industry Trends and Forecast to 2028

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.

Contact us:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgemarketresearch.com

[researchnesterinsights]

Metastatic Bladder Cancer  Market Industry Statistics, Overview, Trends and Forecast 2029

Research Nester released a report titled “Metastatic Bladder Cancer Market: Global Demand Analysis & Opportunity Outlook 2029” which delivers detailed overview of the global metastatic bladder cancer market in terms of market segmentation by cancer type, treatment type, and region.

Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.

The metastatic bladder cancer market is projected to grow with a moderate CAGR during the forecast period, i.e., 2021-2029, on account of the rising elderly population and the increasing investment in the developing of new therapies. According to the data collected from National Center for Biotechnology Information, bladder cancer is the tenth most common type of cancer in the world and accounted for 2.1% of all cancer deaths worldwide in 2018.

The market is segmented by cancer type into urothelial carcinoma, squamous cell carcinoma, adenocarcinoma, and others. Among these segments, the urothelial carcinoma segment is anticipated to hold the largest share by the end of 2021 in the metastatic bladder cancer market as a result of being the most prevalent category of metastatic bladder cancer. The high incidence of urothelial carcinoma can be linked to the increasing tobacco consumption globally which is a major risk factor for it. On the basis of treatment type, the market is segmented into surgery, chemotherapy, immunotherapy, radiotherapy, targeted therapy, and others.

Download Sample of This Strategic Report: https://www.researchnester.com/sample-request-3022

On the basis of region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, out of which, the metastatic bladder cancer market in the Asia Pacific is projected to grow at the highest CAGR throughout the forecast period. Currently, the market in North America holds the largest share. This can be attributed to the presence of leading healthcare providers in the region, especially in the United States, who are extensively involved in the research and development for innovative metastatic bladder cancer treatment procedures.

Rising Elderly Population and Increasing Investment in the Development of New Therapies to Drive Market Growth

According to the United Nations, it is estimated that by 2050, every one in six people will be 65 years or older, i.e., 16% of the total world population. Along with this, the number of persons above 80 years or older is also projected to triple by the end of 2050.

Age is one of the most predominant risk factors for the development of metastatic bladder cancer. It has been observed that individuals whose age is above 65 years or more possess a high risk of having metastatic bladder cancer. Additionally, the increasing investment in research and development relating to metastatic bladder cancer in recent years is also expected to boost the market growth in upcoming years. However, the expensive cost of cancer therapies and lack of awareness in low income economies are some of the factors that are estimated to restrain market growth in the near future.

“The Final Report will cover the impact analysis of COVID-19 on this industry.”

Download/Request Sample Copy of Strategic Report:  https://www.researchnester.com/sample-request-3022

This report also provides the existing competitive scenario of some of the key players of the global metastatic bladder cancer market which includes company profiling of Pfizer Inc. (NYSE: PFE), Sanofi (EPA:SAN), GlaxoSmithKline PLC (LON:GSK), Elli Lilly and Company (NYSE: LLY), AstraZeneca PLC (LON: AZN), Bristol Myers Squibb (NYSE: BMY), Roche Holding AG (SWX:RO), Celgene Corporation, and Accord Healthcare Ltd. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global metastatic bladder cancer market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

About Research Nester

Research Nester is a one-stop service provider with a client base in more than 50 countries, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives for their future investment while avoiding forthcoming uncertainties. With an out-of-the-box mindset to produce statistical and analytical market research reports, we provide strategic consulting so that our clients can make wise business decisions with clarity while strategizing and planning for their forthcoming needs and succeed in achieving their future endeavors. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds.

Contact for more Info:

AJ Daniel

Email: info@researchnester.com

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919

Leave a Reply

You must be logged in to post a comment.

[businessindustry]

Urothelial Cancer Treatment Market Forecast, Analysis | Reports and Insights | 2024-2032

The Reports and Insights, a leading market research company, has recently releases report titled “Urothelial Cancer Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2031.” The study provides a detailed analysis of the industry, including the global Urothelial Cancer Treatment Market Size share, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Urothelial Cancer Treatment Market?

The global urothelial cancer treatment market was US$ 1.1 Billion in 2022. Furthermore, the global market to register revenue CAGR of 9.5% over the forecast period and account for market size of US$ 2.5 Bn in 2031.

What are Urothelial Cancer Treatment?

Urothelial cancer treatment varies depending on the cancer's stage and severity. It usually involves surgery to remove the tumor or affected organ, such as the bladder, followed by chemotherapy or immunotherapy to kill any remaining cancer cells and prevent recurrence. In cases where the cancer has spread, additional treatments like radiation therapy or targeted therapy may be used. Treatment plans are personalized based on the individual's health and preferences, with the goal of achieving the best outcomes while minimizing side effects.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2055

What are the growth prospects and trends in the Urothelial Cancer Treatment industry?

The urothelial cancer treatment market growth is driven by various factors. The market for urothelial cancer treatment is experiencing notable growth, primarily due to the escalating global incidence of this cancer type. Key drivers include a growing elderly population, lifestyle shifts increasing cancer risks, and advancements in treatment methodologies. The introduction of innovative therapies like immunotherapy and targeted therapy is also propelling market expansion. Nevertheless, obstacles such as the high cost of treatment and restricted access to advanced cancer care in developing areas could impede market growth. Hence, all these factors contribute to urothelial cancer treatment market growth.

What is included in market segmentation?

The report has segmented the market into the following categories:

By Treatment Type:

Chemotherapy

Immunotherapy

Targeted Therapy

Surgery

Radiation Therapy

By End-Use:

Hospitals

Cancer Treatment Centers

Ambulatory Surgical Centers

Specialty Clinics

Others

By Drug Type:

Platinum-based Chemotherapy Drugs

Immune Checkpoint Inhibitors

FGFR Inhibitors

PD-L1 Inhibitors

Others

By Cancer Stage:

Non-Muscle Invasive Bladder Cancer (NMIBC)

Muscle Invasive Bladder Cancer (MIBC)

Metastatic Urothelial Carcinoma

Others

Segmentation By Region:

North America:

United States

Canada

Asia Pacific:

China

India

Japan

Australia & New Zealand

Association of Southeast Asian Nations (ASEAN)

Rest of Asia Pacific

Europe:

Germany

The U.K.

France

Spain

Italy

Russia

Poland

BENELUX (Belgium, the Netherlands, Luxembourg)

NORDIC (Norway, Sweden, Finland, Denmark)

Rest of Europe

Latin America:

Brazil

Mexico

Argentina

Rest of Latin America

The Middle East & Africa:

Saudi Arabia

United Arab Emirates

South Africa

Egypt

Israel

Rest of MEA (Middle East & Africa)

Who are the key players operating in the industry?

The report covers the major market players including:

Merck & Co., Inc.

Genentech, Inc. (Roche)

Bristol Myers Squibb

Eli Lilly and Company

AstraZeneca

Seattle Genetics

Johnson & Johnson (Janssen Pharmaceuticals)

Pfizer Inc.

Novartis International AG

Sanofi S.A.

View Full Report: https://www.reportsandinsights.com/report/Urothelial Cancer Treatment-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: sales@reportsandinsights.com Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1

[jesse-pinkman123]

Immune Checkpoint Inhibitors Market Size, Trends, Shares Forecast 2018-2026

The global Immune Checkpoint Inhibitors Market by Drug Class (Programmed Death Receptor-1 (PD-1) Inhibitors (Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Others (Spartalizumab), Programmed Death-Ligand 1 (PD-L1) Inhibitors (Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi)), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) Inhibitors (Ipilimumab (Yervoy)), Indoleamine-2,3-dioxygenase (IDO) Inhibitors, Lymphocyte-Activation Gene 3 Inhibitors)), By Cancer Type (Lung Cancer, Head & Neck Cancers, Skin Cancer (Melanoma and Merkel Cell Carcinoma), Blood Cancer (Lymphoma), Bladder Cancer (Urothelial Carcinoma), Renal/Kidney Cancer, Colorectal Cancer, Breast Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 10,543.8 million in 2017, and is projected to exhibit a CAGR of 11.8% over the forecast period (2018 – 2026).

Increasing prevalence of cancer is expected to boost the demand for immune checkpoint inhibitors. Also, innovative drug launches along with robust pipeline is expected to boost the global immune checkpoint inhibitors market growth over the forecast period. Major manufacturers are investing into R&D to develop immune-checkpoint therapies by understanding tumor functions and ways to combat them. Manufacturers are focusing on upgrading available immune checkpoint inhibitors as well as developing new immune checkpoint inhibitors for cancer treatment. For instance, AstraZeneca’s Durvalumab (Imfinzi) was approved in 2017, as immune checkpoint inhibitor, which blocks interaction of PD-L1 with PD-1 and CD80. In December 2017, Bristol-Myers Squibb received approval for Nivolumab (Opdivo) in adjuvant treatment of melanoma. In March 2017, Avelumab (Bavencio), jointly developed by EMD Serono, and Pfizer, Inc. received U.S. Food & Drug Administration (FDA) approval for the treatment of metastatic merkel cell carcinoma. In 2017, the U.S. FDA granted accelerated approval to immunotherapy product- TECENTRIQ (atezolizumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC).

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2560

Browse 46 Market Data Tables and 41 Figures spread through 238 Pages and in-depth TOC on Global Immune Checkpoint Inhibitors Market by Drug Class (Programmed Death Receptor-1 (PD-1) Inhibitors (Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Others (Spartalizumab), Programmed Death-Ligand 1 (PD-L1) Inhibitors (Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi)), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) Inhibitors (Ipilimumab (Yervoy)), Indoleamine-2,3-dioxygenase (IDO) Inhibitors, Lymphocyte-Activation Gene 3 Inhibitors)), By Cancer Type (Lung Cancer, Head & Neck Cancers, Skin Cancer (Melanoma and Merkel Cell Carcinoma), Blood Cancer (Lymphoma), Bladder Cancer (Urothelial Carcinoma), Renal/Kidney Cancer, Colorectal Cancer, Breast Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies),  and region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2025

Research and development by leading as well as small and mid-sized players in immune checkpoint inhibitors market is expected to support global immune checkpoint inhibitors market growth. For instance, Oncolytics Biotech, Inc. announced research collaboration with the Keck School of Medicine of University of Southern California (USC), in order to develop a combination therapy of Reolycin (Oncolytics Biotech’s product), Keytruda, Velcade, and dexamethasone for the treatment of multiple myeloma in May 2018. Furthermore, in January 2018, Keytruda, developed by Merck & Co. reported slow liver cancer progression in Phase 2 trial. Immuno-oncology combination therapies are also under research for various cancer indications.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/immune-checkpoint-inhibitors-market-2560

In January 2018, the U.S. Food & Drug Administration (FDA) granted breakthrough therapy status to Lenvima-Keytruda combo for advanced kidney cancer. Furthermore, in February 2018, Opdivo-Yervoy combination therapy showed delayed disease progression in patients with advanced non-small cell lung cancer. Moreover, Genentech combination therapy Tecentriq and Avastin delayed kidney cancer progression in Phase III trials in December 2017. AstraZeneca Plc’s Imfinzi (Durvalumab) showed delayed non-small cell lung cancer progression in Phase III trials in November 2017.

Key Takeaways of the Global Immune Checkpoint Inhibitors Market:

The global immune checkpoint inhibitors market is expected to exhibit a CAGR of 11.8% over the forecast period. This is attributed to presence of several leading manufacturers who are focusing on introducing innovative therapies through extensive research and development such as Bristol Myers Squibb, Novartis, and Pfizer, Inc.

Biopharmaceutical companies are developing a robust pipeline of immune-checkpoint inhibitor combination therapies due to their increasing demand. The U.S. Food & Drug Administration (FDA) has approved a number of immune checkpoint inhibitors including Yervoy (anti-CTLA-4), Opdivo and Keytruda (anti-PD1) and Tecentriq (anti-PD-L1).

Immuno-checkpoint inhibitor combination therapies are expected to change the market scenario over the forecast period, owing to positive results in the clinical trials

Research partnerships and collaborations to develop new drugs by various market players is supporting growth of the market, as competitors are striving to gain competitive edge in the market

Major players operating in the global immune checkpoint inhibitors market include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc., Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2560

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737

[healthcare-market]

Active Pharmaceutical Ingredients (API) Market Projected to Witness Vigorous Expansion by 2026

The global active pharmaceutical ingredients market was valued at US$ 162,000.0 Mn in 2017 and is projected to expand at a cumulative annual growth rate (CAGR) of 5.4% from 2018 to 2026, according to a new report published by Transparency Market Research (TMR) titled ‘Global Active Pharmaceutical Ingredients (API)- Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2028.’ The report suggests that increase in the use of pharmaceuticals globally is estimated to boost the active pharmaceutical ingredients market between 2018 and 2026. North America and Asia Pacific are projected to dominate the global market, owing an increase in the demand for efficient and effective management of APIs manufacturing, high health care IT budgets, and high adoption of accelerated regulatory review of innovative medicines. The market in Europe is projected to expand at a moderate growth rate of 5.0% during the forecast period. The active pharmaceutical ingredients market in Latin America is likely to expand at a moderate pace during the forecast period. Key factors driving the market in Brazil are rapid improvement in health care infrastructure and increase in purchasing power of the people. In addition, health care companies are striving to cut hospitalization costs while offering better services to patients in the country.

Request a PDF Sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1690

Increase in Government Prioritization of Biomedical Innovation Globally to Fuel Market

Governments across the world have prioritized biomedical innovation. Accelerated regulatory review by the FDA for innovative medicines boosts the global active pharmaceutical ingredients market. The FDA has approved more than 45 drugs in 2017. Drugs approved by the FDA are used for the treatment of relapsed or refractory acute lymphoblastic leukemia, relapsed breast cancer, moderate-to-severe plaque psoriasis, advanced or metastatic urothelial carcinoma, acute bacterial skin infections, Chagas disease, open-angle glaucoma or ocular hypertension, type 2 diabetes mellitus, and septic or other distributive shock.

Increase in the Incidence of Acute and Chronic Diseases Globally to Fuel Market

Rise in the prevalence of cancer, cardiovascular diseases, and diabetes; sedentary lifestyles; and a rise in the aging population are key factors driving the active pharmaceutical ingredients (API) market. As per the National Cancer Institute, in 2016, there were an estimated 15.5 million cancer survivors in the U.S.. The number of cancer survivors is expected to increase to 20.3 million by 2026. As per an EU government agency survey, almost 49 million people were living with cardiovascular disease in the EU in 2017. Lung cancer is the leading cause of cancer deaths in Asia Pacific. China alone accounts for more than 50% of all cancer cases in this region. Changes in lifestyle and socio-cultural factors are propelling the incidence of cervical cancer. Major countries affected by breast cancer in Asia Pacific are India, Thailand, and China.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1690

The Dominant In-house API Manufacturing Segment is Estimated to Lose Market Share During the Forecast Period

The in-house API manufacturing segment includes the active pharmaceutical ingredients produced for the internal consumption of a pharmaceutical company. The revenue of the in-house API manufacturing segment has declined in the past few years due to outsourcing of API production. High degree of competition and reduced profitability are the key factors attributed to the increased preference for outsourcing API production over in-house API manufacturing.

The Synthetic Chemical API Segment is Projected to Lead the Active Pharmaceutical Ingredients Market

Around 66.0% of the APIs currently available in the market constitute synthetic chemical APIs, popularly known as small molecules. Although the top-selling drugs are biologics, the number of these drugs is quite small as compared to the small molecule drugs. Currently, over 3,000 small molecule drugs are available in the market, which provides significant business opportunities for synthetic API production.

Anti-infective Drugs and Cardiovascular Drugs Lead the Market

In terms of therapeutic, the market has been categorized into anti-infective drugs, metabolic disorders drugs, cardiovascular drugs, oncology drugs, central nervous system drugs, respiratory diseases drugs and others. The anti-infective drugs segment is likely to account for a leading share of the market during the forecast period. Increase in the incidence of cardiovascular diseases is anticipated to fuel the cardiovascular drugs segment during the forecast period.

Request for Analysis of COVID19 Impact on Active Pharmaceutical Ingredients (API) Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1690

Asia Pacific Offers Significant Business Development Opportunity

North America and Asia Pacific accounted for a key share of the global active pharmaceutical ingredients market in 2017. The regions are likely to gain market share by the end of 2026. High adoption of biotech/biological APIs and government initiatives to promote innovative medicine have contributed to the leading share held by these regions in the global active pharmaceutical ingredients market. Asia Pacific is projected to be a highly attractive region of the active pharmaceutical ingredients market. The market in Asia Pacific is projected expand at a high CAGR of over 6.0% during the forecast period, due to the significant scale of drug production in the region. China and India are part of top three countries globally in terms of drug volume production. The market in Latin America and Middle East & Africa is anticipated to expand at a moderate growth rate during the forecast period.

Buy now Active Pharmaceutical Ingredients (API) Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=1690&ltype=S

Key Trend of Acquisitions and Collaborations among Leading Players to Increase Geographic Presence

The report also provide profiles of leading players operating in global active pharmaceutical ingredients market. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Boehringer Ingelheim International GmbH., Merck & Co., Inc., Novartis AG, F. Hoffmann-La Roche Ltd., and Bayer AG are a few leading players operating in the global active pharmaceutical ingredients market. The companies account for a significant market share. Companies operating in the market are aiming to increase their geographic presence by means of strategic acquisitions and collaborations with leading players in respective domains and geographies. In March 2018, Ardena Holding NV acquired ChemConnection, a leading contract manufacturer of novel active pharmaceutical ingredients and nanomedicines.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.co.uk/news-releases/carbon-therapy-segment-in-particle-therapy-market-to-grow-at-exponential-growth-rate-from-2018-to-2026-tmr-848789727.html

https://www.prnewswire.com/news-releases/strides-in-positive-airway-pressure-devices-market-help-reduce-worldwide-prevalence-of-obstructive-sleep-apnea-valuation-to-rise-at-cagr-of-7-8-from-2019-to-2027-tmr-301136571.html

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

[pharmaphorumuk]

FDA looks at pulling speedy approvals for three cancer drugs

FDA advisors will scrutinise three cancer immunotherapies granted conditional approvals at a three-day meeting this week, to see if they should stay on the market. 

The Oncologic Drugs Advisory Committee (ODAC) is scheduled to look at the data for the three drugs – Merck & Co’s Keytruda (pembrolizumab), Bristol-Myers Squibb’s Opdivo (nivolumab) and Roche’s Tecentriq (atezolizumab) – across six types of cancer.

In all cases the drugs generated promising data in mid-stage studies that was enough to support preliminary approval as part of the FDA’s efforts to bring new therapies to patients more quickly. However, they failed larger follow-up studies designed to confirm those initial findings.

The last few months have seen four occasions in which drugmakers have opted to voluntarily withdraw approvals for cancer drugs that failed confirmatory trials, but this is a rare example of the ODAC convening a meeting to review drugs with a view to potentially voiding their approvals.

The earlier voluntarily withdrawn approvals were for Opdivo and Keytruda for relapsed small cell lung cancer (SCLC), and Tecentriq and AstraZeneca’s Imfinzi (durvalumab) for relapsed urothelial carcinoma (UC).

Today (27 April), the ODAC is due to look at Tecentriq in combination with BMS/Celgene’s Abraxane (nab-paclitaxel) for people with advanced triple-negative breast cancer (TNBC) whose tumours express PD-L1, an indication which was provisionally approved by the FDA in 2019 on the strength of the Impassion130 study.

A similar trial called Impassion131 of Tecentriq with regular paclitaxel flopped, and even suggested patients treated with paclitaxel alone may have fared better. Briefing documents published by the FDA ahead of the meeting suggest that discussion will focus on ongoing trials that may serve as alternative confirmatory studies.

On Wednesday (28 April), the focus will shift to Keytruda and Tecentriq as first-line treatments for UC patients unable to be treated with cisplatin-containing chemotherapy – which got the go-ahead in 2017 and 2018, respectively.

Since then, Merck KGaA and Pfizer have picked up a full FDA approval for their immunotherapy Bavencio (avelumab) as a first-line maintenance therapy for this type of cancer, and that could potentially raise the level of evidence needed to keep Keytruda and Tecentriq available to patients.

The following day, the ODAC turns its attention to Keytruda for third-line treatment of recurrent, PD-L1-expressing gastric or gastroesophageal junction adenocarcinoma – cleared in 2017 – and the approvals of Keytruda and Opdivo as second-line therapies for hepatocellular carcinoma (HCC) previously treated with Bayer/Onyx’ Nexavar (sorafenib) in 2018 and 2020.

When the meeting was announced last month, Richard Pazdur, head of the FDA’s Office of Oncologic Diseases, said that it “creates an opportunity for external oncology experts and patients with cancer to share input and perspective with the FDA”.

He said that the deliberations could result in drugs remaining on the market or recommendations for additional clinical trials.

Since the start of the FDA’s accelerated approval programme for cancer drugs in 1992, more than 155 have been granted but only 10 (6%) have been withdrawn, according to the FDA, which has been criticised for failing to follow up when confirmatory trials either aren’t carried out or have negative results.

Writing in the New England Journal of Medicine (NEJM) last week, Pazdur and Julia Beaver said that only a small percentage of drugs fail to have their initial benefit confirmed, arguing this should be viewed “not as a failure of accelerated approval but rather as an expected trade-off in expediting drug development that benefits patients with severe or life-threatening diseases”.

The FDA has used opted to revoke an accelerated cancer approval only once, back in 2011 when Roche’s Avastin (bevacizumab) lost its license as a breast cancer treatment in combination with chemotherapy.

In 2016, the agency was criticised by the US Government Accountability Office (GAO) for not gathering enough post-marketing data on drugs granted expedited approvals.

The post FDA looks at pulling speedy approvals for three cancer drugs appeared first on .

from https://pharmaphorum.com/news/fda-looks-at-pulling-speedy-approvals-for-three-cancer-drugs/

[rishabh3210blog]

Global Biologics Market Size & Growth Analysis Report, 2020-2026

The global biologics market is estimated to grow at a CAGR of 8.6% during the forecast period. Increasing approvals of biologics drugs are offering a significant opportunity for market growth. In June 2020, EMD Serono, and Pfizer Inc. declared the approval of the US FDA supplemental Biologics License Application for BAVENCIO (avelumab). The drug is approved for the maintenance treatment of patients suffering from metastatic or locally advanced urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy. It is the first immunotherapy that has shown a statistically potential improvement in the whole survival in the first-line setting in urothelial carcinoma. Therefore, the approval of avelumab by the US FDA is one of the potential advances for the treatment of metastatic or locally advanced urothelial carcinoma in 30 years.

Get Report Sample Copy @ https://www.omrglobal.com/request-sample/biologics-market

Further, in October 2020, Cadila Pharmaceuticals revealed two similar biologics in the Indian market. This includes NuPTH, a teriparatide similar biologic, and Cadalimab, a similar biologic of the auto-immune treatment adalimumab. Cadila revealed four new products in India since July 2020. In August 2020, Cadila has also declared the introduction of a further similar biologic in India. The drug is sold as NuPTH, which is a similar biologic of teriparatide. This drug is a form of parathyroid hormone that is aimed for the treatment of osteoporosis by promoting bone formation. It can also be utilized in other patient groups with an enhanced risk of fracture.

(Get 15% Discount on Buying this Report)

A Full Report of Global Biologics Market  is Available at: https://www.omrglobal.com/industry-reports/biologics-market

Scope of the Global Biologics Market

Market Coverage

Market number available for 2019-2026

Base year- 2019

Forecast period- 2020-2026

Segment Covered- By Product and Application

Regions Covered- North America, Europe, Asia-Pacific, and Rest of the World

Competitive Landscape- AbbVie Inc., Amgen Inc., Eli Lilly and Co., F. Hoffman-La Roche AG, and Boehringer Ingelheim GmbH

Recent Strategic Initiatives in the Global Biologics Market

In February 2019, Alder presented a Biologics License Application (BLA) to the US FDA for eptinezumab. During 2020, Lundbeck expects to present eptinezumab for European Union approval, followed by proposals for approval in other regions across the globe including Japan and China. This acquisition will accelerate Lundbeck’s late-stage pipeline and offering access to novel capabilities in the field of monoclonal antibody treatment.

In June 2018, Boehringer Ingelheim declared its plans to invest nearly $269.2 million into a new biological development centre (BDC) at the company’s R&D site in Biberach, Germany. The center is a major building block that encourages the company’s long-term strategy to enhance the share of pipeline’s biologicals.

Global Biologics Market-Segmentation

By Product

Antibody Therapeutics

Vaccines        

Cell Therapy

Gene Therapy

Others

By Application

Cancer

Autoimmune Diseases

Infectious Diseases

Others

Global Biologics Market– Segment by Region

North America          

United States

Canada

Europe

Germany

United Kingdom

France

Spain

Italy

Rest of Europe

Asia-Pacific    

China

Japan

India

Rest of Asia-Pacific

Rest of the World

Company Profiles

Amgen Inc.

AstraZeneca plc (UK)

Aurobindo Pharma Ltd.

Biocon Ltd.

Biological E. Limited (BE)

Boehringer Ingelheim GmbH (Germany)

Bristol Myers Squibb Co. (UK)

Cipla Ltd. (India)

Reasons to Buying From us –

We cover more than 15 major industries, further segmented into more than 90 sectors.

More than 120 countries are for analysis.

Over 100+ paid data sources mined for investigation.

Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/biologics-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404

[clevertimetravelpaper]

Urothelial Cancer Treatment Market - Global Market Size, Analysis, Share, Research, Business Growth, Technology, Industry and Forecast

Urothelial Cancer Treatment Market  is expected to experience market growth over the forecast period from 2020 to 2027. Global Urothelial Cancer Treatment Market Data Bridge Market research report provides analysis and insights information on various factors that are expected to prevail throughout the forecast period, while providing their impact on market growth.   

Urothelial carcinoma is a disease that begins when the urothelial cells lining the bladder change and grow abnormally, resulting in the formation of a mass called a    tumor  . Transitional cell carcinoma, another name for urothelial carcinoma, is the most common type of bladder cancer. Other parts of the urinary tract, such as the ureter, urethra, and renal pelvis, are also lined with urothelial cells. Therefore, people with bladder cancer are also more likely to develop tumors in these places. Complications arise when bladder cancer can spread to deeper layers of the bladder and get out of control. The main symptoms of urothelial cancer include blood in the  urine  , pain, changes in urination habits, bladder irritation,  edema  , night sweats, weight loss, and fever.

Get Sample PDF of the Report –  https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-urothelial-carcinoma-treatment-market

This Urothelial Cancer Treatment Market report details recent new developments, trade regulations, import and export analysis, production analysis, value chain optimization, share analysis market trends, the impact of national and local market players and analyzes emerging revenue segments. , market growth strategy analysis, market size, market categories, global growth, niche and application dominance, product approvals, product launches, geographic expansion, technological innovations in the market. For more insights on Urothelial Cancer Treatment Market, contact Data Bridge Market Research for Analyst Profiles and our team will help you make informed market decisions for market growth.   

Global Urothelial Cancer Treatment Market Scope   and Market Size

The urothelial cancer treatment market is segmented on the basis of type, treatment, diagnostic test, end user, and distribution channel. Growth between different market segments helps you gain knowledge related to the different growth factors expected to prevail in the market and develop different strategies to help you identify the differences between key application areas and target markets.

On the basis of type, the urothelial cancer treatment market is segmented into papillary carcinoma and flat carcinoma.

On the basis of treatment, the urothelial cancer treatment market is segmented into chemotherapy,    radiotherapy    and immunotherapy.

Based on diagnostic tests, the urothelial cancer treatment market is segmented into urine cytology, biopsy,    computed tomography  , ultrasound imaging, cystoscopy and others.

On the basis of end-user, the urothelial cancer treatment market is segmented into    hospitals  , specialty clinics, and others. 

Based on distribution channels, the urothelial cancer treatment market has been segmented into hospital pharmacies, retail pharmacies, and others.

To Obtain More Insights on Market Analysis, Visit Research Report Summary @:-  https://www.databridgemarketresearch.com/reports/global-urothelial-carcinoma-treatment-market

Country Level Analysis  of Global Urothelial Cancer Treatment Market 

The Urothelial Cancer Treatment market is analyzed and market size information is provided by country, type, treatment, diagnostic test, end-user and distribution channel mentioned above. The countries covered in the global Urothelial Cancer Treatment market report are United States, Canada, Mexico, North America, Brazil, Argentina, Peru, Rest of South America South, South America, Germany, France, United Kingdom, Netherlands, Switzerland and Belgium. , Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest from Asia-Pacific, Saudi Arabia, Asia-Pacific, United Arab Emirates, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, Middle East and Africa.

North America holds the largest market share owing to the presence of major product manufacturers in the region, increasing R&D activities, healthcare expenditures, and skilled professionals. Asia-Pacific is expected to witness growth in the coming years due to increasing research and development in the urothelial cancer treatment market.

The national segment of the Urothelial Cancer Treatment market report also provides individual market influencers and regulatory changes in the national market impacting current and future market trends. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import and export tariffs are some of the major indicators used to forecast market conditions in each country. In addition, the presence and availability of global brands and the challenges due to high or infrequent competition from local and national brands, the impact of sales channels are taken into account during the predictive analysis of country data.

Competitive Landscape and Global Urothelial Cancer Treatment Market Share Analysis 

 Urothelial Cancer Treatment market competitive landscape provides details of competitors. Details include company profile, company financials, revenue generated, market potential, R&D investments, plans for new markets, global presence, production locations and facilities, company strengths and weaknesses, product launches, clinical trial pipeline, product approvals, patents, product scope and scope, application benefits, lifeline curve technological. The data points provided above are only related to the business focus related to the Urothelial Cancer Treatment market.  

Key Players of Urothelial Cancer Treatment Market are Merck, AstraZeneca, Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Dendreon Pharmaceuticals LLC, Eisai, Inc., Genentech, Sanofi, Hoffmann-La-Roche Ltd, UroGen Pharma Ltd, Immunomedics, Konninklije Philips NV, Olympus Corporation, Pacific Edge, IDL Biotech, Agilent Technologies, Inc.  and other national and global players. Market share data for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America is available separately . DBMR analysts understand competitive advantage and provide competitive analysis for each competitor individually.

Browse Complete TOC at:- https://www.databridgemarketresearch.com/toc/?dbmr=global-urothelial-carcinoma-treatment-market

Top Healthcare Reports:-

Ion Chromatography Mass Spectrometry Market  - Industry Size, Share, Trends and Growth Prospects  https://www.databridgemarketresearch.com/reports/global-ion-chromatography-mass-spectrometry-market

Glow Discharge Mass Spectrometry Market  - Industry Size, Share, Trends and Growth Prospects  https://www.databridgemarketresearch.com/reports/global-glow-discharge-mass-spectrometry-market

Asia Pacific Ion Chromatography Mass Spectrometry Market  - Industry Size, Share, Trends and Growth Prospects   https://www.databridgemarketresearch.com/reports/asia-pacific-ion-chromatography-mass-spectrometry- market

Europe Ion Chromatography Mass Spectrometry Market  - Industry Size, Share, Trends and Growth Prospects  https://www.databridgemarketresearch.com/reports/europe-ion-chromatography-mass-spectrometry-market

North America Ion Chromatography Mass Spectrometry Market  - Industry Size, Share, Trends and Growth Prospects    https://www.databridgemarketresearch.com/reports/north-america-ion-chromatography-mass- spectrometry-market

About Data Bridge Market Research:

An absolute way to predict the future is to understand today's trends! Data Bridge Market Research positions itself as an unconventional and innovative market research and advisory company with unparalleled resilience and an integrated approach. We are committed to uncovering the best market opportunities and providing effective insights for your business to thrive in the market. Data Bridge strives to provide appropriate solutions to complex business challenges and initiate a simple decision-making process. Data Bridge is a collection of pure wisdom and experience, formulated and built in Pune in 2015.

Data Bridge Market Research has more than 500 analysts from various industries. We serve over 40% of Fortune 500 companies worldwide and have a global network of over 5,000 clients. Data Bridge knows how to create satisfied customers who rely on our services and rely on our hard work. We are pleased with our glorious customer satisfaction score of 99.9%.

Contact us:-

Data Bridge Market Research

USA: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:  -corporatesales@databridgemarketresearch.com

[wiseguyreportresearch]

Urothelial Carcinoma Treatment Market Analysis, Historic Data and Forecast 2020

Market Outline: Urothelial Carcinoma Treatment Market

Urothelial carcinoma is also called as transitional cell carcinoma. Urothelial carcinoma is a type of cancer that occurs in the urinary system and it is most common type of bladder cancer of the ureter, urachus and urethra. Urothelial cell carcinoma starts from transitional epithelium. Potential signs in recognising the urothelial carcinoma include blood in urine, persistent back pain and painful urination. Generally, urothelial cell carcinoma is diagnosed using the blood tests and scanning. Treatment may include anticancer drugs, antibacterials to reduce or stop the growth of cancer cells and other treatments such as radiotherapy or nephroureterectomy are indicated.

ALSO READ : https://icrowdnewswire.com/2021/01/06/urothelial-carcinoma-treatment-2021-global-market-outlook-research-trends-and-forecast-to-2023/

Market Dynamics: Urothelial Carcinoma Treatment Market

Urothelial carcinoma treatment market is driven by the increase in global prevalence of the bladder cancer and emergence of potential diagnostics for identifying bladder cancer. Furthermore, increase funding for R&D activities to develop new cancer therapies and growing awareness regarding early diagnosis of cancer as a result of awareness programs or other initiatives by government and non-government organizations are expected to boost the urothelial carcinoma treatment market over the forecast period. However, high cost of R&D for development of new drugs and presence of generic drugs in the market are expected to hamper the market revenue growth during the forecast period.

ALSO READ : http://www.marketwatch.com/story/fitness-equipment-market-2021-industry-size-share-price-trend-and-forecast-to-2026-2021-01-29

Market Scope: Urothelial Carcinoma Treatment Market

Global urothelial carcinoma treatment market is segmented based on type of treatment, and distribution channel

Based on treatment, it segmented into

Immunotherapy

Radiotherapy

Chemotherapy

Others

Based on distribution channel, it is segmented into

Hospital Pharmacies

Retail Pharmacies

Others

Market Summary: Urothelial Carcinoma Treatment Market

ALSO READ : http://www.marketwatch.com/story/global-businesses-and-enterprise-ai-market-projection-by-industry-size-share-movements-by-trend-analysis-growth-status-revenue-expectation-to-2026-2021-01-27

Global urothelial carcinoma treatment market growth is driven by increase in global prevalence rate of bladder cancer. According to World Cancer Research Fund International, bladder cancer is the ninth most common cancer in the world and in the year 2012 - 430,000 new cases were diagnosed. The market has many large players and actively developing and launching of new products related to urothelial carcinoma treatment. For instance, in March 2017, Bavarian Nordic A/S collaborated with F.Hoffmann-La Roche Ltd to evaluate the Tecentriq and CV301 drugs in urothelial cancer treatment. Furthermore, promising pipeline drugs for treatment of urothelial carcinoma such as B-701 (in phase 2 clinical trials by BioClin Therapeutics, FGFR-3 Antibody (By Eli Lilly and Company in phase 1 clinical trials) are expected to boost future revenue forecasts.

Region Analysis: Urothelial Carcinoma Treatment Market

ALSO READ : http://www.marketwatch.com/story/global-natural-deodorants-market-2020-segmentation-demand-growth-trend-opportunity-and-forecast-to-2026-2021-01-21

Geographically, urothelial carcinoma treatment market has been segmented into Latin America, Europe, Asia- Pacific, North America, and the Middle East & Africa. North America expected to grow at significant rates owing to growing prevalence of bladder cancer, increase in awareness and well-established healthcare infrastructure. American Cancer Society estimates that, about 79,030 new cases of bladder cancer in 2017 in U.S. alone. Europe region expected to grow at notable rates owing to the factors such as growing awareness related to early diagnosis of cancer and developed healthcare infrastructure coupled with prevalence rates of urothelial cancer. Asia Pacific region is expected exhibit significant growth opportunity owing to developing healthcare infrastructure and low R&D costs.

Market Participants: Urothelial Carcinoma Treatment Market

Some of the players in Market are GlaxoSmithKline plc (U.K.), Genentech, Inc. (U.S.), Novartis AG (Switzerland), Dendreon (U.S.), Merck KGaA (Germany), Eisai Co. (Japan), Sanofi S.A. (France), and Bristol-Myers Squibb (U.S.) to name a few

Notable Market Developments: Urothelial carcinoma Treatment Market

In May 2017, U.S. Food and Drug Administration approved Sereno Inc.’s (E. Merck KG) BAVENCIO (avelumab) for the treatment of urothelial carcinoma.

In February 2017, U.S. FDA has approved Bristol-Mayer Squibb Company’s OPDIVO (Nivolumab) for the treatment of urothelial carcinoma.

ALSO READ : http://www.marketwatch.com/story/global-fingerprint-mobile-biometrics-market-2020-share-trend-segmentation-and-forecast-to-2026-2021-01-19

[factmrresearch1]

IMMUNE CHECKPOINT INHIBITORS MARKET

Immune checkpoint inhibitors are a part of immuno-oncology therapies, which involves use of patients’ immune system to fight against cancer. Immuno-oncology uses novel immunotherapies such as immune checkpoint inhibitors that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immune checkpoint inhibitors are immunotherapy products that block the proteins, which stop immune system from attacking the cancer cells. These drugs block certain checkpoint proteins such as CTLA-4, PD-1, and PD-L1. Manufacturers are engaged in research and development of immune checkpoint inhibitors as standalone therapies as well as in combination with other immuno-oncology products. Immune checkpoint inhibitors work against a wide variety of cancer, which include non-small cell lung cancer, lymphoma, skin cancer, breast cancer, and others. Depending on the functioning of these therapies they are further classified into subtypes such as programmed death receptor-1 (PD-1) inhibitors, programmed death-ligand 1 (PD-L1) inhibitors, and cytotoxic t-lymphocyte antigen 4 (CTLA-4) inhibitors. Commercially available immune checkpoint inhibitors include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Introduction of novel immune checkpoint inhibitors with less side effects is driving global immune checkpoint inhibitors market growth

Cancer treatment has become more refined with improved treatment success rate due to improved therapeutic outcomes. This has been possible due to better understanding of the disease pathophysiology, functioning of the tumor cells, and effective ways to tackle with the same. Immune checkpoint inhibitors exhibit lesser side effects as compared to conventional cancer therapies such as chemotherapy, radiation therapy, and others. Manufactures are developing immune checkpoint inhibitors, which are tailored to attack or block particular targets. For instance, Iplimumab, a human monoclonal antibody, which blocks cytotoxic T-lymphocyte-associated antigen-4 is available. Furthermore, agents focusing on specific immune regulatory checkpoints programmed death-1 (PD-1) and programmed death ligand-1 and 2 (PD-L1) such as Nivolumab, Atezolimumab, and Pembrolizumab are being used for cell lung cancer. Moreover, in April 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to immunotherapy product- TECENTRIQ (atezolizumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC), who are not eligible for cisplatin chemotherapy, which is currently in the clinical phase 4.

The global immune checkpoint inhibitors market size was valued at US$ 10,543.8 million in 2017, and is expected to witness a robust CAGR of 11.8% over the forecast period (2018 – 2026).

 Figure No.1: Global Immune Checkpoint Inhibitors Market Share (%), by Region, 2018 and 2026

                        Source: Coherent Market Insights Analysis (2017)

Active research and development by leading players as well as small innovative organizations are expected to boost growth of the immune checkpoint inhibitors market

Immune checkpoint inhibitor is gaining significant traction as an efficient therapy for cancer treatment worldwide owing to less side effects, and targeted therapeutic effect. Therefore, various pharmaceuticals, biotech companies, universities, and cancer centers are focusing on investing in this segment. According to the Tufts Center for the Study of Drug Development (CSDD) report, 2016, currently, over 130 biotech and 20 pharma companies are developing immuno-oncology therapies, thereby fueling immune checkpoint inhibitors market growth in the forecast period. Also, according to the New York-based, Cancer Research Institute (CRI), 2017, currently 2,004 immuno-oncology agents including 940 in clinical stage and 1,064 in preclinical stage are under development. Leading players are actively investing in research and development in oncology treatment through various collaborations and individual research studies, owing to benefits associated with immune-oncology therapies. Advent of innovative immune-oncology therapies such as immune checkpoint inhibitors, have supported growth of the market. For instance, in 2016, AbbVie and the University of Texas MD Anderson Cancer Center entered into a three-year agreement for focusing on immune system’s complete potential to fight against cancer.

Figure No.2: Global Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis and Forecast and Y-o-Y Growth (%) (2018-2026)

                           Source: Coherent Market Insights Analysis (2017)

Table No.1: Atezolizumab (Tecentriq) Years of Approval and Indications

Year of Approval

Atezolizumab  (Tecentriq) Indication

2016

Urothelial  Carcinoma

2016

Specific  Type of Metastatic Lung Cancer

2017

Initial  Treatment for Certain People with Advanced Bladder Cancer

2018

Initial  Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

2019

Combination  With Abraxane Accelerated Approval for People

With  PD-L1-Positive, Metastatic Triple-Negative Breast Cancer

Source: Company Annual Reports

However, high cost of immuno-oncology therapies, which is unaffordable to low and middle income population is restraining immune checkpoint inhibitors market growth. For instance, Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer cost around US$ 2,250 for a vial of 50 mg.

Some of the major players operating in the immune checkpoint inhibitors market include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc., Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.